OR WAIT 15 SECS
New York, NY – CHDI Foundation, a non-profit biomedical research organization exclusively dedicated to developing therapies for Huntington’s disease (HD), today announced that it will be implementing Greenphire’s two flagship payment technology platforms, the eClinicalGPS and the ClinCard System, to enhance its payment capability in the upcoming Enroll-HD global observational study. CHDI will be utilizing the eClinicalGPS platform to automatically calculate and deliver site and investigator payments in local currency across 29 countries. Greenphire's ClinCard System will also be implemented in order to deliver real-time electronic travel expense payments to study participants in local currency. The new relationship with CHDI expands on the rapid global adoption of the eClinicalGPS platform and the ClinCard System’s established record of success with pharmaceutical, biotechnology, medical device, and contract research organization clients.
Enroll-HD is a longitudinal clinical observational study for HD patients that represents a continuation of CHDI’s ongoing REGISTRY and COHORT HD clinical studies. Enroll-HD will include sites in North America, Latin America, Europe, and Australia/New Zealand. Already under IRB review in the United States and Canada, Enroll-HD ultimately aims to include over 230 sites across 29 countries. This diverse and international study offers excellent research parameters within which to leverage Greenphire’s global solutions to drive value and efficiency for CHDI, participating research sites, and study participants.
CHDI President Robi Blumenstein commented on the decision to automate Enroll-HD’s global payment processes, saying “At CHDI our mission is to develop drugs that will make a difference in HD patients’ lives in the quickest possible time. We are delighted to work with Greenphire to ensure our payments worldwide are made more quickly, more simply, and more securely so that our study teams can focus their energy on our patients, our sites, and the clinical success of our studies.”
A joint analysis by Greenphire and CHDI estimated that integrating Greenphire’s technology platforms will considerably reduce costs associated with managing and delivering site and participant payments when compared to manual processes. Given Enroll-HD’s international profile, CHDI was particularly concerned that managing local compliance and foreign exchange complications across dozens of countries would incur significant cost and risk.
Joseph Giuliano, Director of Clinical Operations at CHDI, also emphasized the importance of global payment functionality in the global study. “Enroll-HD will be an important research platform for the HD research community, industry partners and investigators developing therapies for HD that will improve outcomes for patients,” he said. “As a global study, Enroll-HD needs a set of technologies that can benefit all our sites around the world, and throughout our planning stages the Greenphire team has shown they are capable of delivering efficient payment solutions that meet our needs.”
Greenphire CEO Sam Whitaker also expressed enthusiasm with the CHDI relationship, commenting that “CHDI occupies a unique space in the clinical trials community, and its passionate, single-minded mission to further drug development is a model for the industry. The Enroll-HD study is an ambitious step towards a targeted global clinical research model, and Greenphire is thrilled to participate. As seamless global payments become a reality for more studies and sponsors, so does seamless global research, and we are proud to stand with CHDI at the cutting edge.”